Pandemic threats are increasing as globalization, urbanization, and encroachment on animal habitats cause infectious outbreaks to become more frequent and severe. It is imperative that the United States build a pipeline of medical countermeasure development, beginning with basic scientific research and culminating in approved therapies. This report assesses preparedness for families of viral pathogens of pandemic potential and offers recommendations for steps the U.S. government can take to prepare for future pandemics.

U.S. policymakers are increasingly concerned about the national security implications of U.S. investments in China, and some are considering a new regime for reviewing outbound investment security. The authors identify the main U.S. investors active in the Chinese artificial intelligence market and the set of AI companies in China that have benefitted from U.S. capital. They also recommend next steps for U.S. policymakers to better address the concerns over capital flowing into the Chinese AI ecosystem.

CSET Non-Resident Senior Fellow Kevin Wolf testified before the Senate Banking Committee on U.S. export control policy and opportunities.

CSET's Dr. Caroline Schuerger, Dr. Steph Batalis, and Vikram Venkatram submitted this comment with recommendations for the National Biotechnology and Biomanufacturing Initiative.

CSET Non-Resident Senior Fellow Kevin Wolf testified before the House Foreign Affairs Oversight and Accountability Subcommittee regarding U.S. export control policy and his recommendations going forward.

CSET Non-Resident Senior Fellow Kevin Wolf testified before the United Kingdom Parliament on export controls and Russia.

U.S. federal policymakers have recently gained the authority to block government agencies and private organizations from using foreign technologies that pose national security risks. But securing U.S. networks will require them to wield those powers effectively and better coordinate supply chain security efforts across all levels of government. The authors provide an overview of federal- and state-level procurement bans and recommend ways to build stronger defense against foreign technology threats.

Biosafety Level-3 laboratories (BSL-3) are an essential part of research infrastructure and are used to develop vaccines and therapies. The research conducted in them provides insights into host-pathogen interactions that may help prevent future pandemics. However, these facilities also potentially pose a risk to society through lab accidents or misuse. Despite their importance, there is no comprehensive list of BSL-3 facilities, or the institutions in which they are housed. By systematically assessing PubMed articles published in English from 2006-2021, this paper maps institutions that host BSL-3 labs by their locations, augmenting current knowledge of where high-containment research is conducted globally.

Geopolitical tensions between the United States and China have sparked an ongoing dialogue in Washington about the phenomenon of “decoupling”—the use of public policy tools to separate the multifaceted economic ties that connect the two powers. This issue brief provides a historical lens on the efficacy of one specific aspect of this broader decoupling phenomenon: using export controls and related trade policies to prevent a rival from acquiring the equipment and know-how to catch up to the United States in cutting-edge, strategically important technologies.

China is banking on applying AI to biotechnology research in order to transform itself into a “biotech superpower.” In pursuit of that goal, it has emphasized bringing together different aspects of the development cycle to foster multidisciplinary research. This data brief examines the emerging trend of co-location of AI and biotechnology researchers and explores the potential impact it will have on this growing field.